RT Journal Article
T1 Co-adjuvant therapy efficacy of catechin and procyanidin b2 with docetaxel on hormone-related cancers in vitro
A1 Núñez Iglesias, María Jesús
A1 Novío Mallón, Silvia
A1 García Santiago, Carlota
A1 Pérez Muñuzuri, Mª Elena
A1 Martínez, María-Carmen
A1 Santiago, José-Luis
A1 Boso, Susana
A1 Gago, Pilar
A1 Freire-Garabal Núñez, Manuel
K1 Antitumor activity
K1 Catechin
K1 Docetaxel
K1 Docetaxel-sensitization
K1 Hormone-related cancer
K1 Natural substances
K1 Plant co-adjuvant therapy
K1 Procyanidin
AB Prostate (PC) and breast cancer (BC) are heterogeneous hormonal cancers. Treatment resistance and adverse effects are the main limitations of conventional chemotherapy treatment. The use of sensitizing agents could improve the effectiveness of chemotherapeutic drugs as well as obviate these limitations. This study analyzes the effect of single catechin (CAT), procyanidin B2 (ProB2) treatment as well as the co-adjuvant treatment of each of these compounds with docetaxel (DOCE). We used PC- and BC-derived cell lines (PC3, DU-145, T47D, MCF-7 and MDA-MB-231). The short and long-term pro-apoptotic, anti-proliferative and anti-migratory effects were analyzed. RT-qPCR was used to discover molecular bases of the therapeutic efficacy of these compounds. ProB2 treatment induced a two- to five-fold increase in anti-proliferative and pro-apoptotic effects compared to single DOCE treatment, and also had a more sensitizing effect than DOCE on DU145 cells. Regarding BC cells, ProB2- and CAT-mediated sensitization to DOCE anti-proliferative and pro-apoptotic effects was cell-independent and cell-dependent, respectively. Combined treatment led to high-efficacy effects on MCF-7 cells, which were associated to the up-regulation of CDKN1A, BAX, caspase 9 and E-cadherin mRNA under combined treatment compared to single DOCE treatment. CAT and ProB2 can enhance the efficacy of DOCE therapy on PC and BC cells by the sensitizing mechanism.
PB MDPI
SN 1422-0067
YR 2021
FD 2021-07-02
LK https://hdl.handle.net/10347/43388
UL https://hdl.handle.net/10347/43388
LA eng
NO Núñez-Iglesias, M.J.; Novio, S.; García, C.; Pérez-Muñuzuri, M.E.; Martínez, M.-C.; Santiago, J.-L.; Boso, S.; Gago, P.; Freire-Garabal, M. Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro. Int. J. Mol. Sci. 2021, 22, 7178. https://doi.org/10.3390/ ijms22137178
NO This research included in Interreg Atlantic Area Programme 2014–2020 was funded by European Regional Development Fund (ERDF) under management of Centro para el Desarrollo Tecnológico Industrial (CDTI). INNGAL-AGROMARSALUD 2013 project [grant number ITC-20133014].
DS Minerva
RD 28 abr 2026